ArticleEuropean journal of drug metabolism and pharmacokinetics2026
Population Pharmacokinetics of Melphalan in Pediatric Patients Undergoing Autologous Hematopoietic Stem Cell Transplantation with Various Conditioning Regimens.
Article in European journal of drug metabolism and pharmacokinetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04937634 (Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Pharmacokinetic Study of Melphalan in Pediatric Hematopoietic Stem Cell Transplantation
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
objectiveMelphalan is an alkylating agent used in conditioning regimens for hematopoietic stem cell transplantation (HSCT) in pediatric patients. In this study, we aimed to develop a population pharmacokinetic (PK) model of melphalan in pediatric patients undergoing various conditioning regimens.
methodsIn total, 20 pediatric patients who received one or two consecutive doses of melphalan were included in this study. PK data were analyzed using a nonlinear mixed-effects model. Evaluated covariates included body weight (WT), sex, estimated glomerular filtration rate (eGFR), creatinine, hematocrit, prior radiation therapy, concomitant drugs (conditioning regimen), and blood albumin levels. Systemic melphalan exposure was simulated using covariates included in the final model.
resultsParticipant ages ranged from 0.6 to 17.4 years. Melphalan PK was best described by a two-compartment model with proportional residual error. Significant covariates were concomitant busulfan and creatinine on clearance, and WT on clearance and the central and peripheral volumes of distribution. Final parameter estimates (normalized to a WT of 28 kg) were as follows: clearance, 24.9 L/h; central compartment volume, 13.4 L; intercompartmental clearance, 14.5 L/h; and peripheral compartment volume, 7.37 L. Simulations indicated that concomitant busulfan was associated with an approximately 1.17 to 1.19-fold increase in melphalan exposure, while patients with lower WT (7.9 kg) showed an approximately 1.12 to 1.13-fold higher exposure than those with high WT (66.7 kg) within the same regimen group.
conclusionsWe developed a preliminary PK model for melphalan in pediatric patients with varying WT levels, conditioning regimens, and renal functions. Our findings suggest that concomitant busulfan contribute to variability in melphalan exposure, indicating its potential application in personalized therapy. (NCT04937634).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.